Skip to main navigation Skip to search Skip to main content

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic

Project Details

StatusFinished
Effective start/end date1/09/23 → 30/09/26

Funding

  • AstraZeneca: A$161,082.00